Dietary Intervention for NSCLC Patients Treated With ICI

Recruiting now · Not applicable

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.

Key facts

Study ID

NCT05805319

Run by

Centre hospitalier de l'Université de Montréal (CHUM)

People needed

80

Starts

2023-04-27

Expected to finish

2026-03-30

Last updated by the study team

2024-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed, informed consent
• Age 18 years or older
• Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI
• Ability to eat solid foods

You may not qualify if…

• Severe dietary allergies (e.g. shellfish, nuts, seafood)
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Where it is running

• Centre hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.